UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13D

 

 

Under the Securities Exchange Act of 1934

(Amendment No. 5)*

 

 

Viracta Therapeutics, Inc. (f/k/a Sunesis Pharmaceuticals, Inc.)

(Name of Issuer)

Common Stock, $0.0001 par value

(Title of Class of Securities)

92765F108

(CUSIP Number)

Louis S. Citron, Esq.

New Enterprise Associates

1954 Greenspring Drive, Suite 600, Timonium, MD 21093

(410) 842-4000

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

August 11, 2020

(Date of Event which Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

CUSIP No. 92765F108

13D Page 2 of 8 Pages    

 

Item 1. Security and Issuer.

 

This Amendment No. 5 (“Amendment No. 5”) to Schedule 13D amends and supplements the statement on Schedule 13D originally filed on April 13, 2009, as amended on November 17, 2009, July 9, 2010, August 13, 2014 and January 7, 2016, relating to common stock, $0.0001 par value (the “Common Stock”) of Viracta Therapeutics, Inc. (f/k/a Sunesis Pharmaceuticals, Inc.) (the “Issuer”) having its principal executive office at 395 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080.

 

Certain terms used but not defined in this Amendment No. 5 have the meanings assigned thereto in the Schedule 13D (including Amendment No. 1, Amendment No. 2, Amendment No. 3 and Amendment No. 4 thereto). Except as specifically provided herein, this Amendment No. 5 does not modify any of the information previously reported on the Schedule 13D, as amended (including Amendment No. 1, Amendment No. 2, Amendment No. 3 and Amendment No. 4 thereto).

 

 

Item 2. Identity and Background.

 

This statement is being filed by:

 

(a) Growth Equity Opportunities Fund, LLC (“GEO”);

 

(b) New Enterprise Associates 12, Limited Partnership (“NEA 12”), which is the sole member of GEO;

 

(c) NEA Partners 12, Limited Partnership (“NEA Partners 12”), which is the general partner of NEA 12; and NEA 12 GP, LLC (“NEA 12 GP”), which is the general partner of NEA Partners 12; and

 

(d) Forest Baskett (“Baskett”), Patrick J. Kerins (“Kerins”) and Scott D. Sandell (“Sandell”) (collectively, the “Managers”) and Michael James Barrett, Peter J. Barris and Krishna S. Kolluri. The Managers are the individual managers of NEA 12 GP.

 

The persons named in this Item 2 are referred to individually herein as a “Reporting Person” and collectively as the “Reporting Persons.”

 

The address of the principal business office of GEO, NEA 12, NEA Partners 12, NEA 12 GP and Sandell is New Enterprise Associates, 1954 Greenspring Drive, Timonium, MD 21093. The address of the principal business office of Baskett is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, California 94025. The address of the principal business office of Kerins is New Enterprise Associates, 5425 Wisconsin Avenue, Suite 800, Chevy Chase, MD 20815.

 

 

Item 3. Source and Amount of Funds or Other Consideration.

 

Not applicable.

 

 

Item 4. Purpose of Transaction.

 

Not applicable.

 

 

Item 5. Interest in Securities of the Issuer.

 

Each of the Reporting Persons has ceased to own beneficially five percent or more of the Issuer’s Common Stock.

 

 

Item 7. Material to be Filed as Exhibits.

 

Exhibit 1 – Agreement regarding filing of joint Schedule 13D.

 

Exhibit 2 – Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

 

 

 

 

CUSIP No. 92765F108

13D Page 3 of 8 Pages    

SIGNATURE

 

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

Date:         March 10, 2021.

 

 

Growth Equity Opportunities Fund, LLC

 

By:              NEW ENTERPRISE ASSOCIATES 12, LIMITED PARTNERSHIP

Sole Member

 

By:     NEA PARTNERS 12, LIMITED PARTNERSHIP

General Partner

 

By: NEA 12 GP, LLC
General Partner

 

By:    /s/ Scott D. Sandell                            

Scott D. Sandell

Manager

 

 

NEW ENTERPRISE ASSOCIATES 12, LIMITED PARTNERSHIP

 

By:              NEA PARTNERS 12, LIMITED PARTNERSHIP

General Partner

 

By:      NEA 12 GP, LLC

General Partner

 

By:    /s/ Scott D. Sandell                          

Scott D. Sandell

Manager

 

 

NEA PARTNERS 12, LIMITED PARTNERSHIP

 

By: NEA 12 GP, LLC

General Partner

 

By:      /s/ Scott D. Sandell                           

Scott D. Sandell

Manager

 

 

NEA 12 GP, LLC

 

By:              /s/ Scott D. Sandell                       

    Scott D. Sandell

    Manager

 

 

 

 
 

CUSIP No. 92765F108

13D Page 4 of 8 Pages    

 

 

 

 

 

 

                            *                            

Michael James Barrett

 

 

                            *                            

Peter J. Barris

 

 

                            *                            

Forest Baskett

 

 

                            *                            

Patrick J. Kerins

 

 

                            *                            

Krishna S. Kolluri

 

 

                            *                            

Scott D. Sandell

 

 

 

 

 

 

By:     */s/ Sasha Keough             

Sasha Keough

As attorney-in-fact

 

This Amendment No. 5 to Schedule 13D was executed by Sasha Keough on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached as Exhibit 2.

 

 

 

 

 

 

 

 

 

 

 
 

CUSIP No. 92765F108

13D Page 5 of 8 Pages    

 

EXHIBIT 1

 

AGREEMENT

 

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of Viracta Therapeutics, Inc. (f/k/a Sunesis Pharmaceuticals, Inc.)

 

EXECUTED this 10th day of March, 2021.

 

 

Growth Equity Opportunities Fund, LLC

 

By:              NEW ENTERPRISE ASSOCIATES 12, LIMITED PARTNERSHIP

Sole Member

 

By:     NEA PARTNERS 12, LIMITED PARTNERSHIP

General Partner

 

By: NEA 12 GP, LLC
General Partner

 

By:    /s/ Scott D. Sandell                             

Scott D. Sandell

Manager

 

 

NEW ENTERPRISE ASSOCIATES 12, LIMITED PARTNERSHIP

 

By:              NEA PARTNERS 12, LIMITED PARTNERSHIP

General Partner

 

By:      NEA 12 GP, LLC

General Partner

 

By:    /s/ Scott D. Sandell                         

Scott D. Sandell

Manager

 

 

NEA PARTNERS 12, LIMITED PARTNERSHIP

 

By: NEA 12 GP, LLC

General Partner

 

By:      /s/ Scott D. Sandell                         

Scott D. Sandell

Manager

 

 

NEA 12 GP, LLC

 

By:              /s/ Scott D. Sandell                       

    Scott D. Sandell

    Manager

 

 

 

 

 
 

CUSIP No. 92765F108

13D Page 6 of 8 Pages    

 

 

 

 

 

                            *                            

Michael James Barrett

 

 

                            *                            

Peter J. Barris

 

 

                            *                            

Forest Baskett

 

 

                            *                            

Patrick J. Kerins

 

 

                            *                            

Krishna S. Kolluri

 

 

                            *                            

Scott D. Sandell

 

 

 

 

 

By:     */s/ Sasha Keough             

Sasha Keough

As attorney-in-fact

 

This Agreement relating to Schedule 13D was executed by Sasha Keough on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached hereto as Exhibit 2.

 

 

 

 

 

 

 

 

 

 

 

 

 

CUSIP No. 92765F108

13D Page 7 of 8 Pages    

EXHIBIT 2

 

POWER OF ATTORNEY

 

KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Louis S. Citron, Timothy Schaller, Sasha Keough and Stephanie Brecher, and each of them, with full power to act without the others, his or her true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his or her capacity as a direct or indirect general partner, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he or she might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his or her substitutes, may lawfully do or cause to be done by virtue hereof.

 

IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 13th day of March, 2017.

 

 

/s/ M. James Barrett            

M. James Barrett

 

/s/ Peter J. Barris                

Peter J. Barris

 

/s/ Forest Baskett                

Forest Baskett

 

/s/ Ali Behbahani                 

Ali Behbahani

 

/s/ Colin Bryant                   

Colin Bryant

 

/s/ Carmen Chang               

Carmen Chang

 

/s/ Anthony A. Florence, Jr.

Anthony A. Florence, Jr.

 

/s/ Carol G. Gallagher          

Carol G. Gallagher

 

/s/ Dayna Grayson               

Dayna Grayson

 

/s/ Patrick J. Kerins             

Patrick J. Kerins

 

/s/ P. Justin Klein                

P. Justin Klein

 

 

 

 

 

CUSIP No. 92765F108

13D Page 8 of 8 Pages    

 

 

 

 

/s/ Vanessa Larco               

Vanessa Larco

 

/s/ Joshua Makower             

Joshua Makower

 

/s/ Mohamad H. Makhzoumi

Mohamad H. Makhzoumi

 

/s/ Edward T. Mathers         

Edward T. Mathers

 

/s/ David M. Mott                

David M. Mott

 

/s/ Sara M. Nayeem            

Sara M. Nayeem

 

/s/ Jason R. Nunn                

Jason R. Nunn

 

/s/ Gregory Papadopoulos    

Gregory Papadopoulos

 

/s/ Chetan Puttagunta          

Chetan Puttagunta

 

/s/ Jon Sakoda                     

Jon Sakoda

 

/s/ Scott D. Sandell              

Scott D. Sandell

 

/s/ A. Brooke Seawell          

A. Brooke Seawell

 

/s/ Peter W. Sonsini             

Peter W. Sonsini

 

/s/ Melissa Taunton             

Melissa Taunton

 

/s/ Frank M. Torti                

Frank M. Torti

 

/s/ Ravi Viswanathan           

Ravi Viswanathan

 

/s/ Paul E. Walker               

Paul E. Walker

 

/s/ Rick Yang                      

Rick Yang

 

  

Viracta Therapeutics (NASDAQ:VIRX)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Viracta Therapeutics Charts.
Viracta Therapeutics (NASDAQ:VIRX)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Viracta Therapeutics Charts.